Free Trial
NASDAQ:ASMB

Assembly Biosciences Q3 2025 Earnings Results & Report

Assembly Biosciences logo
$20.18 -2.19 (-9.79%)
Closing price 04:00 PM Eastern
Extended Trading
$20.87 +0.69 (+3.44%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Assembly Biosciences missed analyst earnings expectations but beat on revenue in its Q3 2025 results, released November 10, 2025. The company reported EPS of -$0.72 versus the -$0.50 consensus estimate, while revenue of $10.79 million topped the $7.46 million estimate by $3.33 million.

Earnings Announcement Details

Quarter
Q3 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Assembly Biosciences EPS Results

Actual EPS
-$0.72
Consensus EPS
-$0.50
Beat/Miss
Missed by -$0.22
One Year Ago EPS
N/A
EPS Beat Rate
7 of last 8 quarters

Assembly Biosciences Revenue Results

Actual Revenue
$10.79 million
Expected Revenue
$7.46 million
Beat/Miss
Beat by +$3.33 million
YoY Revenue Growth
N/A

Assembly Biosciences Q3 2025 Earnings FAQ

Assembly Biosciences (NASDAQ:ASMB) reported earnings of -$0.72 per share for Q3 2025, missing the consensus estimate of -$0.50. The report was announced on Monday, November 10, 2025.

Assembly Biosciences reported revenue of $10.79 million for Q3 2025, against a consensus estimate of $7.46 million.

Assembly Biosciences Earnings Headlines

Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.tc pixel
See More Assembly Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Assembly Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Assembly Biosciences and other key companies, straight to your email.

About Assembly Biosciences

Assembly Biosciences (NASDAQ:ASMB) is a clinical-stage biotechnology company focused on developing oral antiviral therapies for viral infections. Its research programs target hepatitis B virus (HBV) and herpesviruses, including herpes simplex virus.

The company’s pipeline includes investigational antiviral candidates designed to interfere with key steps in viral replication. Assembly has also worked with Gilead Sciences on antiviral development, including programs targeting herpesviruses. Its therapies remain under investigation and are not approved medicines.

Based in South San Francisco, California, Assembly Biosciences conducts drug research and development with the goal of addressing significant unmet needs in viral disease treatment.

View Assembly Biosciences Profile